Categories AlphaGraphs, Earnings, Technology

DocuSign (DOCU) Earnings: Q1 profit, revenue top expectations

DocuSign, Inc. (NASDAQ: DOCU), a provider of electronic signature software, Thursday said its first-quarter adjusted earnings more than tripled, aided by strong demand. Both profit and revenues exceeded the market’s projection.

DocuSign Q1 2022 earnings infographic

First-quarter revenues advanced 58% annually to $469.1 million, which is well above experts’ prediction. The top-line benefitted from a strong performance by the core subscription business.

Adjusted earnings jumped to $0.44 per share from $0.12 per share last year. Market watchers were looking for a smaller bottom-line number. On an unadjusted basis, it was a net loss of $8.4 million or $0.04 per share, compared to a loss of $47.8 million or $0.26 per share in the first quarter of 2021.

Read management/analysts’ comments on DocuSign’s Q1 earnings

DocuSign’s stock lost about 12% so far this year and is trading at a near one-year low. It closed Thursday’s regular session sharply lower.

Prior Performance

  • DocuSign (DOCU) Q2 2021 Earnings Infograph
  • DocuSign reports Q1 2021 earnings results


Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock


Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Viewing Highlight